FTC judge dismisses Gemtronics case
This article was originally published in The Tan Sheet
Executive SummaryThe chief administrative law judge appointed by the Federal Trade Commission dismisses the commission's complaint against Franklin, N.C., firm Gemtronics Inc., and its owner, William Isely, because FTC did not adequately prove that Isely or the firm was responsible for deceptive advertising of an herbal remedy advertised falsely as a cancer cure. Isely admitted to selling the product RAAX11, which was "promoted as a mixture of chrysobalanus icaco, a derivative from a tropical bush, and agaricus, a medicinal mushroom," according to FTC, but he denied advertising or selling the product through 1www.agaricus.net, the Web site where the offending claims appeared. FTC has 30 days from Sept. 16 to appeal. FTC charged Gemtronics and Isely with making deceptive and false claims in September 2008 (2"The Tan Sheet" Sept. 22, 2008). The firm was one of 11 challenged under "Operation False Cures," a "law enforcement sweep aimed at peddlers of phony cancer remedies," FTC noted
You may also be interested in...
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.